Zoetis Inc. (NYSE:ZTS) Holdings Boosted by Huntington National Bank

Huntington National Bank boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 5.8% during the third quarter, HoldingsChannel.com reports. The fund owned 249,247 shares of the company’s stock after acquiring an additional 13,757 shares during the period. Huntington National Bank’s holdings in Zoetis were worth $48,698,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Avantax Advisory Services Inc. raised its holdings in shares of Zoetis by 6.2% during the first quarter. Avantax Advisory Services Inc. now owns 10,223 shares of the company’s stock valued at $1,730,000 after buying an additional 596 shares during the last quarter. HBK Sorce Advisory LLC raised its holdings in shares of Zoetis by 1.8% during the first quarter. HBK Sorce Advisory LLC now owns 6,030 shares of the company’s stock valued at $1,020,000 after buying an additional 104 shares during the last quarter. Orion Portfolio Solutions LLC raised its holdings in shares of Zoetis by 10.8% during the first quarter. Orion Portfolio Solutions LLC now owns 66,099 shares of the company’s stock valued at $11,185,000 after buying an additional 6,441 shares during the last quarter. Dorsey & Whitney Trust CO LLC raised its holdings in shares of Zoetis by 16.0% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 4,643 shares of the company’s stock valued at $786,000 after buying an additional 641 shares during the last quarter. Finally, Great Lakes Retirement Inc. raised its holdings in shares of Zoetis by 4.2% during the first quarter. Great Lakes Retirement Inc. now owns 6,794 shares of the company’s stock valued at $1,150,000 after buying an additional 271 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 1.9 %

Zoetis stock opened at $177.28 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm has a market cap of $79.98 billion, a price-to-earnings ratio of 33.32, a price-to-earnings-growth ratio of 2.67 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm’s 50 day moving average price is $187.81 and its two-hundred day moving average price is $180.04.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.36 earnings per share. On average, research analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.97%. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of recent analyst reports. Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.